Measles is spreading across the United States at a pace not seen in more than three decades, and the outbreak has grown so persistent that public health officials are now openly discussing something once considered unnecessary: a dedicated measles treatment.
For most of the modern vaccine era, that conversation was largely theoretical. Measles was rare enough, and the vaccine effective enough, that drugmakers had little incentive to develop antivirals for a disease doctors could usually prevent rather than treat. That calculation is now changing fast.
Confirmed measles cases in the United States have already climbed past 2,300 this year, surpassing the total recorded for all of 2025, which was itself the worst year for measles since the country eliminated the disease in 2000. With more than five months still remaining in 2026, the case count is expected to keep rising. More than 40 jurisdictions have reported measles activity, with dozens of separate outbreaks taking hold in communities with lower vaccination coverage. The overwhelming majority of this year’s patients suffering from the disease, roughly nine in ten, were either unvaccinated or had unknown vaccination status.
That trend line worries infectious disease specialists because measles is, by most measures, the most contagious virus known to circulate among humans. A single infected person can spread measles to a dozen or more susceptible contacts, and the virus can linger in the air for up to two hours after an infected person has left a room. The measles, mumps and rubella vaccine is about 97 percent effective after two doses, and for decades that protection made a specific antiviral treatment feel almost beside the point.
But community immunity depends on keeping vaccination coverage above roughly 95 percent, and that threshold has been slipping. Kindergarten vaccination rates have fallen from just above 95 percent five years ago to under 93 percent today, opening gaps that measles has repeatedly exploited. Once the disease takes hold in an undervaccinated community, physicians currently have almost nothing to offer beyond supportive care: fluids, fever control and vitamin A supplementation to reduce the severity of complications. There is no approved antiviral that can stop the virus from replicating once a patient is infected.
Researchers say that gap is finally getting serious attention. Scientists at Georgia State University have spent years developing an oral antiviral compound aimed at measles and related viruses. Recent animal studies found it could block transmission of a measles-like virus when given shortly before or after exposure, representing one of the first credible steps toward an actual treatment for the disease. Experts caution the drug has not yet been tested in humans and is likely years from approval, but the fact that a dedicated treatment is now being actively pursued reflects how differently officials view the disease.
Epidemiologists have been blunt about the shift in urgency. Health officials who once saw little reason to develop measles-specific drugs now acknowledge that assumption no longer holds. The disease that vaccination nearly erased from American life is reestablishing itself, and each new outbreak increases pressure on researchers to move faster.
Whether a treatment becomes available before the current surge subsides remains uncertain, but for the first time in a generation, treating measles, not just preventing it, is being taken seriously. Public health experts stress that vaccination remains by far the most effective defense, and no future antiviral is expected to replace it.
